株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

変性円盤疾患 : パイプライン製品の分析

Degenerative Disc Disease - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 257809
出版日 ページ情報 英文 66 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
変性円盤疾患 : パイプライン製品の分析 Degenerative Disc Disease - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 66 Pages
概要

変性円盤疾患は、脊柱の椎間板が変性するもので、その変性した椎間板が痛く、動作によっては悪化する場合があります。素因としては、加齢やけが、身体的外傷などによるもので、治療には非ステロイド性抗炎症薬や、筋弛緩薬、鎮痛剤、抗鬱剤などを用います。

当レポートでは、変性円盤疾患の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲
  • 変性円盤疾患 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • AnGes MG, Inc.
  • Asterias Biotherapeutics, Inc.
  • Biogenomics Limited
  • Biopharm GmbH
  • BioRestorative Therapies, Inc.
  • Bone Therapeutics SA
  • DiscGenics, Inc.
  • ISTO Technologies, Inc.
  • TissueGene, Inc.
  • Yuhan Corporation

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8276IDB

Summary

Global Markets Direct's, 'Degenerative Disc Disease - Pipeline Review, H2 2016', provides an overview of the Degenerative Disc Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Degenerative Disc Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease
  • The report reviews pipeline therapeutics for Degenerative Disc Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Degenerative Disc Disease therapeutics and enlists all their major and minor projects
  • The report assesses Degenerative Disc Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Degenerative Disc Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Degenerative Disc Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Degenerative Disc Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Degenerative Disc Disease Overview
  • Therapeutics Development
    • Pipeline Products for Degenerative Disc Disease - Overview
    • Pipeline Products for Degenerative Disc Disease - Comparative Analysis
  • Degenerative Disc Disease - Therapeutics under Development by Companies
  • Degenerative Disc Disease - Therapeutics under Investigation by Universities/Institutes
  • Degenerative Disc Disease - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Degenerative Disc Disease - Products under Development by Companies
  • Degenerative Disc Disease - Products under Investigation by Universities/Institutes
  • Degenerative Disc Disease - Companies Involved in Therapeutics Development
    • AnGes MG, Inc.
    • Asterias Biotherapeutics, Inc.
    • Biogenomics Limited
    • Biopharm GmbH
    • BioRestorative Therapies, Inc.
    • Bone Therapeutics SA
    • DiscGenics, Inc.
    • ISTO Technologies, Inc.
    • TissueGene, Inc.
    • Yuhan Corporation
  • Degenerative Disc Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALLOB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-0101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-0103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BRTX-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CHND-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dibotermin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NuQu - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Poly N-Acetyl Glucosamine Hydrogel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Degenerative Disc Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Degenerative Disc Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-D - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • X-0002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YH-14618 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Degenerative Disc Disease - Dormant Projects
  • Degenerative Disc Disease - Product Development Milestones
    • Featured News & Press Releases
      • May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study
      • Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the 'Clinical Applications of Stem Cells' Conference
      • Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial
      • Feb 09, 2016: BioRestorative Therapies Names Lead Cell-Based Lumbar Disc Therapeutic Product
      • Jan 12, 2015: BioRestorative Therapies Reports Successful Meeting with FDA
      • Nov 24, 2014: BioRestorative Therapies Schedules Pre-IND Meeting With FDA
      • Oct 09, 2014: BioRestorative Therapies Engages Access BIO to Support Advancement of brtxDISC Program into Clinical Studies
      • Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB phase II trial in spine fusion
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Degenerative Disc Disease, H2 2016
  • Number of Products under Development for Degenerative Disc Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Degenerative Disc Disease - Pipeline by AnGes MG, Inc., H2 2016
  • Degenerative Disc Disease - Pipeline by Asterias Biotherapeutics, Inc., H2 2016
  • Degenerative Disc Disease - Pipeline by Biogenomics Limited, H2 2016
  • Degenerative Disc Disease - Pipeline by Biopharm GmbH, H2 2016
  • Degenerative Disc Disease - Pipeline by BioRestorative Therapies, Inc., H2 2016
  • Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H2 2016
  • Degenerative Disc Disease - Pipeline by DiscGenics, Inc., H2 2016
  • Degenerative Disc Disease - Pipeline by ISTO Technologies, Inc., H2 2016
  • Degenerative Disc Disease - Pipeline by TissueGene, Inc., H2 2016
  • Degenerative Disc Disease - Pipeline by Yuhan Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Degenerative Disc Disease - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Degenerative Disc Disease, H2 2016
  • Number of Products under Development for Degenerative Disc Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top